Work

1875P RATIONALE-304: Baseline genetic alterations in tumours with PD-L1 expression ≥50% vs <50% in non-squamous (nsq)-NSCLC treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.2499

Authors: F. Cappuzzo, S. Lu, Y. Yu, L. Liang, K. Naicker, X. Lin, X. Ma, M. Austin Taylor, C.G.M. Ferreira, M. Reck

Institutions: Instituto Nazionale Tumori Regina Elena, Shanghai Jiao Tong University, Shanghai Chest Hospital, Third Affiliated Hospital of Harbin Medical University, BeOne Medicines (Switzerland), German Center for Lung Research, LungenClinic Grosshansdorf

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, International Association for the Study of Lung Cancer, American Society of Clinical Oncology, Novocure, BeiGene, Galecto, Innovent Biologics, PharmaMar, Daiichi Sankyo Europe

OpenAlex ID: W4415940258

FWCI:

Cites:

Cited by:

Related to: